ストックスクリーナーアプリを入手
3.90
13.33%
-0.60
前日終値:
$4.50
開ける：
$4.5
24時間の取引高:
299.71K
Relative Volume:
0.32
時価総額：
$441.65M
収益：
-
当期純損益:
$-18.86M
株価収益率:
-0.2429
EPS:
-16.054
ネットキャッシュフロー:
$-17.68M
1週間 パフォーマンス:
+9.24%
1か月 パフォーマンス:
+156.58%
6か月 パフォーマンス:
+84.83%
1年 パフォーマンス:
+1,085%
1日の値動き範囲:
$3.66
$4.60
1週間の範囲:
$3.20
$4.94
52週間の値動き範囲:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
名前
Indaptus Therapeutics Inc
セクター
電話
(646) 427-2727
住所
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
3.90 | 441.65M | 0 | -18.86M | -17.68M | -16.05 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Indaptus Therapeutics Inc (INDP) 最新ニュース
Indaptus Therapeutics Inc (INDP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Indaptus Therapeutics Inc (INDP) Institutional Confidence - TradingKey
Indaptus Therapeutics Inc (INDP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Indaptus Therapeutics Inc (INDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Indaptus Therapeutics Inc (INDP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Indaptus Therapeutics Inc (INDP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Indaptus Therapeutics Inc (INDP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders - Caledonian Record
INDP Q4 2025 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentNet Income Trends - newsline.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
INDP Q4 2025 Earnings: EPS Misses Estimates, Stock Tumbles 42.62%Quarterly Earnings Report - newsline.com
Indaptus Therapeutics (INDP) Plunges 42% as Selling Pressure IntensifiesUp Down Volume - newsline.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Indaptus Therapeutics, Inc. Files Form 8-K Announcing CEO Change – Junyi Dai Appointed CEO - Minichart
Indaptus Therapeutics Announces Recent Board and Leadership Changes - TipRanks
Indaptus Therapeutics directors David E. Lazar and Avraham Ben-Tzvi resign; Walt A. Linscott steps down as COO - TradingView
Leadership shifts at Indaptus Therapeutics (NASDAQ: INDP) as directors and COO exit - Stock Titan
Indaptus Therapeutics (INDP) Jumps 53.8% Amid Heavy Volume as Investors Focus on Financing/strategic-option Uncertainty - Moomoo
Indaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertainty - Quiver Quantitative
INDP Q4 2025 Earnings: EPS Misses Estimates Amid No Revenue; Stock Surges Over 114%Revenue Beat Analysis - newsline.com
INDP - Finviz
INDP Q4 2025 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Focuses on Pipeline MilestonesMargin Expansion Trends - newsline.com
Indaptus Therapeutics Drops on Cash Runway Worries - Bez Kabli
Indaptus Therapeutics Inc. (INDP) Plunges 9.8% as Shares Approach Key Support ZoneGap Down Bounce Plays - Newser
INDP Q4 2025 Earnings: EPS Misses Estimates as Pre-Clinical Costs Continue, Stock Declines 9%Revenue Growth Outlook - newsline.com
Indaptus Therapeutics Q4 2025 Earnings: EPS Misses Estimates on Minimal Revenue, Stock SurgesFree Cash Flow Trends - The Legal Advocate
Indaptus Therapeutics Inc. (INDP) Q4 2025 Earnings: Deeper Loss, Yet Shares Surge on Pipeline ProgressRevenue Warning Signal - Newser
Indaptus Therapeutics (INDP) Surges 15%: Biotech Stock Breaks Above Key ResistanceMarket Hype Signals - Newser
Earnings Scheduled For May 15, 2026 - Sahm
Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing - Minichart
Indaptus Therapeutics Reports Q1 2026 Financial Results, Management Changes, and Strategic Review Amid Cash Constraints - Minichart
Indaptus Therapeutics reassesses decoy platform as cash dwindles - grafa.com
Indaptus Therapeutics Q1 Financial Analysis - Intellectia AI
Indaptus Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Indaptus Therapeutics (NASDAQ: INDP) cuts R&D, warns on cash runway - Stock Titan
Cash drops at Indaptus (Nasdaq: INDP) as Q1 2026 loss narrows - Stock Titan
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics Q1 net loss narrows as expenses fall - TradingView
Press Release: Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Biotech Indaptus ends Q1 with $1.5M cash, weighs next steps - Stock Titan
TradingKey - TradingKey
INDP | Indaptus Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Indaptus Therapeutics Company Profile & Introduction - Moomoo
INDP Q1'26 Earnings: EPS estimate is (1.87) USD - TradingView
INDP Should I Buy - Intellectia AI
Large holders in Indaptus (INDP) revise stakes and end group status - Stock Titan
Indaptus Therapeutics (INDP) Stock: Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenue - newser.com
Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenueVerified Stock Signals - Newser
Indaptus Therapeutics Appoints Tim Ruan and Johnny Fox Arrowsmith as Independent Directors; Amendment Reflects Legal Name Change - Minichart
Indaptus Therapeutics Inc (INDP) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):